Trial reportNature medicine2024
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Trial report in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed.
- The "Reducing Inflammation for Greater Health Trial (RIGHT)" Study-Concept, Rationale, and Design.Journal of the American Geriatrics Society · 2026Trial
- Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis.Clinical and translational science · 2025Trial
- Association of serum spermidine level with vascular calcification in peritoneal dialysis patients.Renal failure · 2026Article
- Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes.Nature reviews. Nephrology · 2026Review
- Data-Driven Clustering of Secretory Bone and Inflammatory Markers to Subphenotype Patients Undergoing Hemodialysis.Kidney international reports · 2026Article
- Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease.Kidney international reports · 2026Review
- Why Circulating Interleukin-6 Is Not Yet a Standalone Clinically Actionable Biomarker in HFrEF: A Context-of-Use Review.European journal of clinical investigation · 2026Review
- Real-world Evidence for Improvements in Inflammation and Anemia Biomarkers After the Initiation of GLP-1RA in Patients Receiving Hemodialysis.Kidney medicine · 2026Article
- Refining therapeutic targeting of interleukin-6 by signalling mode selectivity.Nature reviews. Drug discovery · 2026Review
- Iron, ESA, and HIF-Inhibitors: Are There Other Opportunities to Improve Anemia of CKD?Journal of clinical medicine · 2026Review
- Targeting Inflammation in Chronic Kidney Disease: Pathophysiological Insights and Emerging Therapeutic Strategies.Journal of clinical medicine · 2026Review
- Targeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies.Immunological reviews · 2026Review
- Hepatic Mechanisms and Therapeutic Target Underpinning Hypercoagulation in Obesity: Insights From Genetic and Transcriptomic Analyses.Exploration (Beijing, China) · 2026Article
- Interplay Between Interleukin-6 Receptor and Lipoprotein(a) in the Causal Association With Cardiovascular Disease.JACC. Basic to translational science · 2026Article
- Mendelian Randomization Reveals Interleukin-6 Receptor-Lipoprotein(a) Interplay With Independent Cardiovascular Risk Reductions.JACC. Basic to translational science · 2026Article
- Cardiovascular outcome of glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitor on end-stage kidney disease patients with heart failure: an emulated target trial in patients with diabetes.Nature communications · 2026Observational
- PCPE-1 promotes cardiac fibrosis with aging and obesity.JCI insight · 2026Article
- A Multidisciplinary Consensus on Cardiovascular Assessment and Management of Kidney Transplant Recipients.Acta Cardiologica Sinica · 2026Article
- From Genes to Membrane Failure: Genetic Determinants of Peritoneal Dialysis Physiology and Outcomes.Genes · 2026Review
- Effect of IL-6 inhibition on lipoprotein(a) levels: A systematic review and meta-analysis.American journal of preventive cardiology · 2026Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation mediated by interleukin-6 (IL-6) is strongly associated with cardiovascular risk. Here we evaluated clazakizumab, a monoclonal antibody targeting the IL-6 ligand, in a phase 2b dose-finding study. Adults with cardiovascular disease and/or diabetes receiving maintenance dialysis with high-sensitivity C-reactive protein (hs-CRP) ≥ 2 mg l
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.